RU2018144187A - Специфический аналог трифторэтилхинолина для применения при лечении apids - Google Patents
Специфический аналог трифторэтилхинолина для применения при лечении apids Download PDFInfo
- Publication number
- RU2018144187A RU2018144187A RU2018144187A RU2018144187A RU2018144187A RU 2018144187 A RU2018144187 A RU 2018144187A RU 2018144187 A RU2018144187 A RU 2018144187A RU 2018144187 A RU2018144187 A RU 2018144187A RU 2018144187 A RU2018144187 A RU 2018144187A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- apds
- triffluorethylquinoline
- apids
- ylamine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 5
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- VMEFULIECWQSDS-OAQYLSRUSA-N N-[(1R)-1-[8-chloro-2-(1-hydroxy-2H-pyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Chemical compound ClC=1C=CC=C2C=C(C(=NC=12)C=1CN(C=CC=1)O)[C@H](C(F)(F)F)NC=1C2=C(N=CN=1)C=CC=N2 VMEFULIECWQSDS-OAQYLSRUSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Claims (6)
1. N-{(R)-1-[8-Хлор-2-(1-оксипиридин-3-ил)хинолин-3-ил]-2,2,2-трифторэтил}пиридо[3,2-d]пиримидин-4-иламин или его фармацевтически приемлемая соль для применения при лечении и/или профилактике активированного фосфоинозитид 3-киназой дельта синдрома (APDS).
2. Способ лечения и/или профилактики активированного фосфоинозитид 3-киназой дельта синдрома (APDS), где способ включает введение пациенту, нуждающемуся в таком лечении, эффективного количества N-{(R)-1-[8-хлор-2-(1-оксипиридин-3-ил)хинолин-3-ил]-2,2,2-трифторэтил}пиридо[3,2-d]пиримидин-4-иламина или его фармацевтически приемлемой соли.
3. Применение N-{(R)-1-[8-хлор-2-(1-оксипиридин-3-ил)хинолин-3-ил]-2,2,2-трифторэтил}пиридо[3,2-d]пиримидин-4-иламина или его фармацевтически приемлемой соли для получения лекарственного средства, предназначенного для лечения и/или профилактики активированного фосфоинозитид 3-киназой дельта синдрома (APDS).
4. Соединение для применения по п. 1, или способ по п. 2, или применение по п. 3, где APDS представляет собой APDS1 и APDS2.
5. Соединение для применения по п. 1, или способ по п. 2, или применение по п. 3, где APDS представляет собой APDS1.
6. Соединение для применения по п. 1, или способ по п. 2, или применение по п. 3, где APDS представляет собой APDS2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608797.5 | 2016-05-19 | ||
| GBGB1608797.5A GB201608797D0 (en) | 2016-05-19 | 2016-05-19 | Therapeutic use |
| PCT/EP2017/061567 WO2017198590A1 (en) | 2016-05-19 | 2017-05-15 | A specific trifluoroethyl quinoline analogue for use in the treatment of apds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018144187A3 RU2018144187A3 (ru) | 2020-06-19 |
| RU2018144187A true RU2018144187A (ru) | 2020-06-19 |
Family
ID=56369612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018144187A RU2018144187A (ru) | 2016-05-19 | 2017-05-15 | Специфический аналог трифторэтилхинолина для применения при лечении apids |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190209567A1 (ru) |
| EP (1) | EP3458065A1 (ru) |
| JP (1) | JP2019516703A (ru) |
| KR (1) | KR20190009790A (ru) |
| CN (1) | CN109152783A (ru) |
| AR (1) | AR108500A1 (ru) |
| AU (1) | AU2017267172A1 (ru) |
| BR (1) | BR112018072450A2 (ru) |
| CA (1) | CA3023974A1 (ru) |
| CL (1) | CL2018003281A1 (ru) |
| CO (1) | CO2018013559A2 (ru) |
| EA (1) | EA201892638A1 (ru) |
| GB (1) | GB201608797D0 (ru) |
| IL (1) | IL262943A (ru) |
| MX (1) | MX2018013770A (ru) |
| RU (1) | RU2018144187A (ru) |
| SG (1) | SG11201809396SA (ru) |
| WO (1) | WO2017198590A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| HK1256419A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途 |
| CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| CN108472295B (zh) | 2015-11-25 | 2022-04-15 | 达纳-法伯癌症研究所股份有限公司 | 二价溴结构域抑制剂及其用途 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| BR112016024538A2 (pt) * | 2014-05-27 | 2017-08-15 | Almirall Sa | sais de adição de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-di-hidro¬pirrolo[1,2-f][1,2,4]triazina-5-carbonitrila |
-
2016
- 2016-05-19 GB GBGB1608797.5A patent/GB201608797D0/en not_active Ceased
-
2017
- 2017-05-15 EA EA201892638A patent/EA201892638A1/ru unknown
- 2017-05-15 RU RU2018144187A patent/RU2018144187A/ru not_active Application Discontinuation
- 2017-05-15 KR KR1020187036873A patent/KR20190009790A/ko not_active Withdrawn
- 2017-05-15 EP EP17723388.9A patent/EP3458065A1/en not_active Withdrawn
- 2017-05-15 CN CN201780030825.XA patent/CN109152783A/zh active Pending
- 2017-05-15 SG SG11201809396SA patent/SG11201809396SA/en unknown
- 2017-05-15 US US16/099,537 patent/US20190209567A1/en not_active Abandoned
- 2017-05-15 MX MX2018013770A patent/MX2018013770A/es unknown
- 2017-05-15 JP JP2018560052A patent/JP2019516703A/ja active Pending
- 2017-05-15 WO PCT/EP2017/061567 patent/WO2017198590A1/en not_active Ceased
- 2017-05-15 CA CA3023974A patent/CA3023974A1/en not_active Abandoned
- 2017-05-15 AU AU2017267172A patent/AU2017267172A1/en not_active Abandoned
- 2017-05-15 BR BR112018072450-5A patent/BR112018072450A2/pt not_active Application Discontinuation
- 2017-05-17 AR ARP170101315A patent/AR108500A1/es unknown
-
2018
- 2018-11-12 IL IL262943A patent/IL262943A/en unknown
- 2018-11-19 CL CL2018003281A patent/CL2018003281A1/es unknown
- 2018-12-13 CO CONC2018/0013559A patent/CO2018013559A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201892638A1 (ru) | 2019-06-28 |
| SG11201809396SA (en) | 2018-11-29 |
| EP3458065A1 (en) | 2019-03-27 |
| IL262943A (en) | 2018-12-31 |
| KR20190009790A (ko) | 2019-01-29 |
| GB201608797D0 (en) | 2016-07-06 |
| CO2018013559A2 (es) | 2019-02-28 |
| US20190209567A1 (en) | 2019-07-11 |
| WO2017198590A1 (en) | 2017-11-23 |
| MX2018013770A (es) | 2019-03-21 |
| AR108500A1 (es) | 2018-08-29 |
| BR112018072450A2 (pt) | 2019-02-19 |
| JP2019516703A (ja) | 2019-06-20 |
| CA3023974A1 (en) | 2017-11-23 |
| RU2018144187A3 (ru) | 2020-06-19 |
| CL2018003281A1 (es) | 2019-01-25 |
| CN109152783A (zh) | 2019-01-04 |
| AU2017267172A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018144187A (ru) | Специфический аналог трифторэтилхинолина для применения при лечении apids | |
| MX2021002321A (es) | Nuevos metodos. | |
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| RU2016141569A (ru) | Комбинации | |
| RU2017105353A (ru) | Соединения | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| JP2016539157A5 (ru) | ||
| WO2011097946A8 (zh) | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| EP4431098A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALPORT SYNDROME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20201006 |